Holen Sie sich die Stockscreener-App
120.05
2.45%
2.87
Schlusskurs vom Vortag:
$117.18
Offen:
$118.82
24-Stunden-Volumen:
1.20M
Relative Volume:
1.07
Marktkapitalisierung:
$6.83B
Einnahmen:
$3.99B
Nettoeinkommen (Verlust:
$463.16M
KGV:
16.91
EPS:
7.1
Netto-Cashflow:
$1.10B
1W Leistung:
+8.35%
1M Leistung:
-5.05%
6M Leistung:
+8.69%
1J Leistung:
+9.85%
1-Tages-Spanne:
$118.75
$120.67
1-Wochen-Bereich:
$111.20
$120.67
52-Wochen-Spanne:
$95.49
$148.06
Jazz Pharmaceuticals Plc Stock (JAZZ) Company Profile
Firmenname
Jazz Pharmaceuticals Plc
Sektor
Branche
Telefon
353-1-634-7800
Adresse
FIFTH FLOOR, WATERLOO EXCHANGE, DUBLIN
Vergleichen Sie JAZZ mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
JAZZ
Jazz Pharmaceuticals Plc
|
120.05 | 6.83B | 3.99B | 463.16M | 1.10B | 7.10 |
|
VRTX
Vertex Pharmaceuticals Inc
|
501.15 | 126.96B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
605.61 | 65.06B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
649.67 | 37.54B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
259.39 | 32.56B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
255.77 | 26.40B | 3.81B | -644.79M | -669.77M | -6.24 |
Jazz Pharmaceuticals Plc Stock (JAZZ) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-03-07 | Hochstufung | UBS | Neutral → Buy |
| 2025-02-26 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2025-02-13 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2024-12-12 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2024-06-05 | Eingeleitet | Goldman | Buy |
| 2024-01-03 | Eingeleitet | Robert W. Baird | Outperform |
| 2023-11-27 | Herabstufung | UBS | Buy → Neutral |
| 2023-09-29 | Eingeleitet | Raymond James | Mkt Perform |
| 2023-06-12 | Fortgesetzt | Wells Fargo | Equal Weight |
| 2022-12-09 | Hochstufung | Goldman | Neutral → Buy |
| 2022-06-14 | Eingeleitet | UBS | Buy |
| 2022-04-06 | Herabstufung | Goldman | Buy → Neutral |
| 2021-11-19 | Fortgesetzt | Goldman | Buy |
| 2021-10-07 | Fortgesetzt | Jefferies | Buy |
| 2021-10-05 | Eingeleitet | Citigroup | Buy |
| 2021-09-23 | Eingeleitet | Needham | Buy |
| 2021-05-19 | Fortgesetzt | JP Morgan | Overweight |
| 2021-04-07 | Fortgesetzt | RBC Capital Mkts | Outperform |
| 2021-02-05 | Bestätigt | H.C. Wainwright | Buy |
| 2021-02-03 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2021-01-29 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2020-12-16 | Eingeleitet | UBS | Buy |
| 2020-11-03 | Bestätigt | H.C. Wainwright | Buy |
| 2020-10-09 | Bestätigt | H.C. Wainwright | Buy |
| 2020-09-14 | Herabstufung | Goldman | Neutral → Sell |
| 2020-09-14 | Fortgesetzt | JP Morgan | Overweight |
| 2020-08-06 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2020-07-28 | Hochstufung | Wolfe Research | Peer Perform → Outperform |
| 2020-07-23 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2020-04-06 | Eingeleitet | Jefferies | Buy |
| 2020-03-12 | Hochstufung | Bernstein | Mkt Perform → Outperform |
| 2020-01-08 | Eingeleitet | Goldman | Neutral |
| 2019-08-21 | Herabstufung | Piper Jaffray | Overweight → Neutral |
| 2019-06-11 | Eingeleitet | Barclays | Overweight |
| 2019-03-20 | Eingeleitet | SunTrust | Buy |
| 2018-12-14 | Eingeleitet | Wolfe Research | Peer Perform |
| 2018-11-08 | Bestätigt | B. Riley FBR | Buy |
| 2018-08-08 | Bestätigt | Stifel | Buy |
| 2018-07-11 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2018-03-23 | Bestätigt | H.C. Wainwright | Neutral |
| 2018-03-19 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
Alle ansehen
Jazz Pharmaceuticals Plc Aktie (JAZZ) Neueste Nachrichten
Jazz Pharmaceuticals to Participate in the BofA Securities 2025 Healthcare Conference - Eagle-Tribune
Jazz Pharmaceuticals to Participate in the BofA Securities 2025 Healthcare Conference | JAZZ Stock News - GuruFocus
Jazz Pharmaceuticals Brings Sleep Disorder and Cancer Treatment Updates to BofA Healthcare Conference - Stock Titan
Buy, Sell Or Hold JAZZ Stock? Key Tips Ahead Of Q1 Earnings - Barchart.com
Buy, Sell or Hold JAZZ Stock? Key Tips Ahead of Q1 Earnings - Zacks Investment Research
PharmaMar Seeks EU Fast-Track Status For ‘Practice-Changing’ ES-SCLC Therapy - insights.citeline.com
Jazz Pharmaceuticals (JAZZ) Earnings Expected to Grow: Should You Buy? - Yahoo Finance
3 Unconventional Cannabis Stocks to Watch in 2025 - Yahoo Finance
With A 14% Return On Equity, Is Jazz Pharmaceuticals plc (NASDAQ:JAZZ) A Quality Stock? - Yahoo Finance
Antisense Oligonucleotides Market Trends, Growth - openPR.com
3 Reasons to Sell JAZZ and 1 Stock to Buy Instead - Yahoo Finance
3 Reasons To Sell JAZZ And 1 Stock To Buy Instead - Barchart.com
Does Jazz Pharmaceuticals (NASDAQ:JAZZ) Deserve A Spot On Your Watchlist? - simplywall.st
Jazz Pharmaceuticals (JAZZ) Gains European Advisory Support for Zanidatamab | JAZZ Stock News - GuruFocus
PTC and Jazz Pharmaceuticals among latest firms to win EU backing for drugs - Seeking Alpha
Jazz Pharmaceuticals Receives Positive EMA Panel Opinion for Zanidatamab to Treat Biliary Tract Cancer - marketscreener.com
Jazz Pharmaceuticals Receives CHMP Positive Opinion for Zanidatamab for the Treatment of Advanced HER2-Positive Biliary Tract Cancer - PR Newswire
Press Release Distribution & PR Platform - ACCESS Newswire
Jazz Pharmaceuticals Showcases Transformative Data at ASCO 2025, Highlighting Advances in Small Cell Lung Cancer, HER2+ Gastroesophageal Cancer and Diffuse Glioma - Placera.se
Major Cancer Breakthrough: New Phase 3 Data Reveals Significant Survival Benefits in Lung Cancer Treatment - Stock Titan
Jazz Pharmaceuticals to Report First Quarter Financial Results on May 6, 2025 | JAZZ Stock News - GuruFocus
Jazz Pharmaceuticals to Report First Quarter Financial Results on May 6, 2025 - PR Newswire UK
TD Cowen maintains Jazz stock Buy rating, $100 target By Investing.com - Investing.com UK
Jazz Pharmaceuticals Acquires Chimerix for $935M - Contract Pharma
Canada Pension Plan Investment Board Purchases 8,000 Shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ) - MarketBeat
Jazz Pharmaceuticals Completes $935 Million Acquisition of Chimerix - marketscreener.com
Jazz Pharmaceuticals acquires Chimerix for $935 million By Investing.com - Investing.com South Africa
Jazz Pharmaceuticals Completes Acquisition of Chimerix | JAZZ St - GuruFocus
Jazz Pharmaceuticals (JAZZ) Completes Acquisition of Chimerix - StreetInsider
Jazz Pharmaceuticals Completes Acquisition of Chimerix - TipRanks
Jazz Pharmaceuticals acquires Chimerix for $935 million - Investing.com
Jazz's $935M Chimerix Buyout Targets First-Ever Treatment for Rare Brain Cancer, FDA Verdict Looms - Stock Titan
JAZZ Vs. HRMY: Which Neuroscience Drugmaker Is The Stronger Play? - Barchart.com
JAZZ vs. HRMY: Which Neuroscience Drugmaker Is the Stronger Play? - Yahoo Finance
Jazz Sues Alvogen Seeking to Block Copy of Defitelio Liver Drug - Bloomberg Law News
JAZZ vs. ARGX: Which Stock Is the Better Value Option? - Yahoo Finance
Why Jazz Pharmaceuticals (JAZZ) is a Top Value Stock for the Long-Term - Yahoo Finance
Is Jazz Pharmaceuticals A Top Cannabis Investment For 2025? - Barchart.com
Is Jazz Pharmaceuticals a Top Cannabis Investment for 2025? - Zacks Investment Research
Zymeworks to Report First Quarter 2025 Financial Results and Host Conference Call on May 8, 2025 - GlobeNewswire Inc.
Pharmaceuticals Stocks Q4 In Review: Jazz Pharmaceuticals (NASDAQ:JAZZ) Vs Peers - Yahoo Finance
Drug Resistant Epilepsy Market reached US$ 0.78 billion in 2022 - openPR.com
Pharma 50: The top pharma companies in the world for 2025 - drugdiscoverytrends.com
Idiopathic Hypersomnia Treatment Market Set to Witness - openPR.com
Jazz Agrees To Fork Out $145m To Resolve Most Xyrem ‘Pay-For-Delay’ Claims - insights.citeline.com
BofA maintains Buy on Jazz Pharmaceuticals stock, target at $213 By Investing.com - Investing.com UK
Where Jazz Pharmaceuticals Stands With Analysts - Benzinga
Jazz (JAZZ) Moves 7.1% Higher: Will This Strength Last? - Nasdaq
Jazz Pharmaceuticals stock hits 52-week low at $99 By Investing.com - Investing.com Canada
Jazz Pharma inks $145M deal to resolve Xyrem antitrust claims - MSN
Jazz Pharmaceuticals at Needham Conference: Strategic Growth Insights By Investing.com - Investing.com South Africa
Finanzdaten der Jazz Pharmaceuticals Plc-Aktie (JAZZ)
Umsatz
Nettogewinn
Free Cashflow
ENV
Jazz Pharmaceuticals Plc-Aktie (JAZZ) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| COZADD BRUCE C | Chairman & CEO |
Apr 01 '25 |
Sale |
123.75 |
1,500 |
185,625 |
440,307 |
0.47%
2.63%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):